Indegene offers value to life sciences, needs price discovery
Synopsis
The Bengaluru-based company is rolling out a ₹1,842 crore initial public offering comprising a fresh issue of ₹760 crore and an offer of sale of ₹1,082 crore. The IPO represents 17% of the company's post-issue paid-up capital. Proceeds of the issue will be used to trim debt and for capex.
ET Intelligence Group: Private equity-backed Indegene provides solutions to the global life sciences industry including biopharma, biotech and medical devices companies enabling them to develop products, undertake market launches and drive sales. The Bengaluru-based company is rolling out a ₹1,842 crore initial public offering comprising a fresh issue of ₹760 crore and an offer of sale of ₹1,082 crore. The IPO represents 17% of the company's
- FONT SIZEAbcSmallAbcMediumAbcLarge
ET
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Get Unlimited Access to The Economic Times
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
